NCT06751940 is a NA clinical trial of Conventional second-line therapy in Colorectal Cancer (CRC), sponsored by The First Affiliated Hospital of Nanchang University.

Who is sponsoring NCT06751940?

NCT06751940 is sponsored by The First Affiliated Hospital of Nanchang University.

What drugs are being tested in NCT06751940?

Interventions in NCT06751940: Conventional second-line therapy, Neoantigen-loaded DC vaccine.

What condition does NCT06751940 study?

NCT06751940 studies Colorectal Cancer (CRC).

Is NCT06751940 still recruiting?

NCT06751940 is currently recruiting now. Last updated 30 December 2024.

Last reviewed 2024-12-30 · How we verify

NCT06751940

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment

Recruiting now NA Last updated 30 December 2024

What this trial tests

NA trial testing Conventional second-line therapy in Colorectal Cancer (CRC) in 10 participants. Currently enrolling.

Timeline

1 September 2024

Primary endpoint
31 August 2026

28 February 2027

Quick facts

Lead sponsor	The First Affiliated Hospital of Nanchang University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 September 2024
Primary completion	31 August 2026
Estimated completion	28 February 2027
Sites	2 locations across China

Drugs / interventions tested

Conventional second-line therapy
Neoantigen-loaded DC vaccine — full drug profile →

Conditions studied

Colorectal Cancer (CRC) — all drugs for Colorectal Cancer (CRC) →

Sponsor

The First Affiliated Hospital of Nanchang University

Who can join

Adults 18 to 70, any sex, with Colorectal Cancer (CRC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded DC vaccine and conventional second-line therapy to patients with colorectal cancer (CRC) progressed after first-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Research progress on mechanisms of tumor immune microenvironment and gastrointestinal resistance to immunotherapy: mini review.
Zhang Z, Wu Y. · · 2025 · cited 4× · PMID 40787471 · DOI 10.3389/fimmu.2025.1641518
Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy.
Peng Y, Zhan L, Shi J, Wang J, et al · · 2025 · PMID 41079643 · DOI 10.1002/mco2.70321

Verify or expand the search:

Other trials of Conventional second-line therapy

Trials testing the same drug.

NCT06751914 — Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment · NA · recruiting

Other recruiting trials for Colorectal Cancer (CRC)

Currently open trials in the same condition.

NCT07448142 — Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
NCT07106892 — Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects Wit · Phase 2 · recruiting
NCT07152210 — Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced C · NA · recruiting
NCT07046468 — Smart Pill for Measuring Gut Health in Colon Inflammation and Colon Cancer · recruiting

Other The First Affiliated Hospital of Nanchang University trials

Trials by the same sponsor.

NCT06639516 — Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Co · NA · not yet recruiting
NCT07136961 — Efficacy and Safety of Robotic-assisted Bronchoscopy Combined With the ICNVA Strategy in Biopsy of Peripheral Pulmonary · NA · active not recruiting
NCT06999031 — A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
NCT06751966 — Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment · NA · recruiting
NCT06752057 — Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06751940 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Nanchang University
Last refreshed: 30 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06751940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing